Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa

Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus

(2023) Katharina Rox et al.   Pharmaceutics

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

(2022) Christopher JL Murray et al.   LANCET

Virulence Factors of Pseudomonas Aeruginosa and Antivirulence Strategies to Combat Its Drug Resistance

(2022) Chongbing Liao et al.   Frontiers in Cellular and Infection Microbiology

Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys

(2022) Craig Fenwick et al.   Nature Microbiology

StarMap: a user-friendly workflow for Rosetta-driven molecular structure refinement

(2022) Wolfgang Lugmayr et al.   Nature Protocols

Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler

(2022) Brieuc Van Nieuwenhuyse et al.   Nature Communications

Influence of tramadol on bacterial burden in the standard neutropenic thigh infection model

(2022) K. Rox   Scientific Reports

Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis

(2021) Avia Watson et al.   Nature Communications

Highly accurate protein structure prediction with AlphaFold

(2021) John Jumper et al.   NATURE

Effective high-throughput isolation of fully human antibodies targeting infectious pathogens

(2021) Lutz Gieselmann et al.   Nature Protocols

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

(2021) Anil Gupta et al.   NEW ENGLAND JOURNAL OF MEDICINE

Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody

(2020) Philipp Schommers et al.   CELL

openPrimeR for multiplex amplification of highly diverse templates

(2020) Christoph Kreer et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Comprehensive Host Cell-Based Screening Assays for Identification of Anti-Virulence Drugs Targeting Pseudomonas aeruginosa and Salmonella Typhimurium

(2020) Julia von Ambüren et al.   Microorganisms

UCSF ChimeraX : Structure visualization for researchers, educators, and developers

(2020) Eric F. Pettersen et al.   PROTEIN SCIENCE

Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis

(2020) Elio Rossi et al.   NATURE REVIEWS MICROBIOLOGY

Monoclonal antibody-based therapies for bacterial infections

(2019) Michael P. Motley et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Genetically diverse Pseudomonas aeruginosa populations display similar transcriptomic profiles in a cystic fibrosis explanted lung

(2019) Adrian Kordes et al.   Nature Communications

Specific antibodies to membrane proteins are effective in complement-mediated killing of Mycoplasma bovis

(2019) Yun-ke Zhang et al.   INFECTION AND IMMUNITY

Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix

(2019) Dorothee Liebschner et al.   Acta Crystallographica Section D-Structural Biology

Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV

(2019) Stefanie A. Ehrhardt et al.   NATURE MEDICINE

Adapting to the Airways: Metabolic Requirements of Pseudomonas aeruginosa during the Infection of Cystic Fibrosis Patients

(2019) La Rosa et al.   Metabolites

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

(2019) Sabue Mulangu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term Microevolution of Pseudomonas aeruginosa Differs Between Mildly and Severely Affected Cystic Fibrosis Lungs

(2018) Jens Klockgether et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa

(2018) R. Jain et al.   Journal of Cystic Fibrosis

Cross-specificity of protective human antibodies against Klebsiella pneumoniae LPS O-antigen

(2018) Tim Rollenske et al.   NATURE IMMUNOLOGY

Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults

(2018) S.O. Ali et al.   CLINICAL MICROBIOLOGY AND INFECTION

Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset

(2017) Zhe Chen et al.   JOURNAL OF INFECTIOUS DISEASES

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

(2017) Marina Caskey et al.   NATURE MEDICINE

Host-directed therapies for bacterial and viral infections

(2017) Stefan H. E. Kaufmann et al.   NATURE REVIEWS DRUG DISCOVERY

Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant Klebsiella pneumoniae

(2017) Meghan E. Pennini et al.   Nature Communications

Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax

(2016) Brent J. Yamamoto et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Obiltoxaximab: First Global Approval

(2016) Sarah L. Greig   DRUGS

Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections

(2016) Stefanie Wagner et al.   JOURNAL OF MEDICINAL CHEMISTRY

Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus

(2016) Wenqian He et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

(2016) D. Corti et al.   SCIENCE

Pseudomonas aeruginosaBacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide

(2015) Joshua T. Thaden et al.   JOURNAL OF INFECTIOUS DISEASES

CTFFIND4: Fast and accurate defocus estimation from electron micrographs

(2015) Alexis Rohou et al.   JOURNAL OF STRUCTURAL BIOLOGY

Antibacterial antibodies gain traction

(2015) Chris Morrison   NATURE REVIEWS DRUG DISCOVERY

A common glycan structure on immunoglobulin G for enhancement of effector functions

(2015) Chin-Wei Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration “Animal Rule”

(2015) Chia-Wei Tsai et al.   Frontiers in Microbiology

A Novel Anti-PcrV Antibody Providing Enhanced Protection against Pseudomonas aeruginosa in Multiple Animal Infection Models

(2014) Paul Warrener et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A multifunctional bispecific antibody protects against Pseudomonas aeruginosa

(2014) A. DiGiandomenico et al.   Science Translational Medicine

IgG Subclasses and Allotypes: From Structure to Effector Functions

(2014) Gestur Vidarsson et al.   Frontiers in Immunology

Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies

(2013) Zhi Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

IgBLAST: an immunoglobulin variable domain sequence analysis tool

(2013) Jian Ye et al.   NUCLEIC ACIDS RESEARCH

Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa

(2012) Bruno François et al.   CRITICAL CARE MEDICINE

ExoS and ExoT ADP Ribosyltransferase Activities Mediate Pseudomonas aeruginosa Keratitis by Promoting Neutrophil Apoptosis and Bacterial Survival

(2012) Y. Sun et al.   JOURNAL OF IMMUNOLOGY

RELION: Implementation of a Bayesian approach to cryo-EM structure determination

(2012) Sjors H.W. Scheres   JOURNAL OF STRUCTURAL BIOLOGY

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega

(2011) F. Sievers et al.   Molecular Systems Biology

The safety and side effects of monoclonal antibodies

(2010) Trevor T. Hansel et al.   NATURE REVIEWS DRUG DISCOVERY

Anti-virulence strategies to combat bacteria-mediated disease

(2010) David A. Rasko et al.   NATURE REVIEWS DRUG DISCOVERY

Treatment with Monoclonal Antibodies againstClostridium difficileToxins

(2010) Israel Lowy et al.   NEW ENGLAND JOURNAL OF MEDICINE

MolProbity: all-atom structure validation for macromolecular crystallography

(2009) Vincent B. Chen et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Role of Pseudomonas aeruginosa type III effectors in disease

(2009) Joanne Engel et al.   CURRENT OPINION IN MICROBIOLOGY

The type III secretion system of Pseudomonas aeruginosa: infection by injection

(2009) Alan R. Hauser   NATURE REVIEWS MICROBIOLOGY

Raxibacumab for the Treatment of Inhalational Anthrax

(2009) Thi-Sau Migone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody response toPseudomonas aeruginosain children with cystic fibrosis

(2009) Lucimar G. Milagres et al.   PEDIATRIC PULMONOLOGY

Persistent Infection withPseudomonas aeruginosain Ventilator-associated Pneumonia

(2008) Ali A. El Solh et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity

(2008) M. Baer et al.   INFECTION AND IMMUNITY

Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning

(2007) Thomas Tiller et al.   JOURNAL OF IMMUNOLOGICAL METHODS